Accelerated Approval pathway for our ST-920 gene therapy product candidate for the treatment of Fabry disease.

Click here to view

CAR-Tregs

Feasibility of manufacture of chimeric antigen receptor-regulatory T cells from patients with end-stage renal disease
July 17th, 2023